Bezlotoxumab for Prevention of Recurrent <i>Clostridioides difficile</i> Infection With a Focus on Immunocompromised Patients.

Askar, Sally F; Kenney, Rachel M; Tariq, Zain; Conner, Ruth; Williams, Jonathan; Ramesh, Mayur; Alangaden, George J

Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection With a Focus on Immunocompromised Patients.

Askar, Sally F; Kenney, Rachel M; Tariq, Zain; Conner, Ruth; Williams, Jonathan; Ramesh, Mayur; Alangaden, George J.

Afiliación

Askar SF; Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA.
Kenney RM; Department of Pharmacy Services, Henry Ford Hospital, Detroit, MI, USA.
Tariq Z; Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI, USA.
Conner R; Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI, USA.
Williams J; Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI, USA.
Ramesh M; Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI, USA.
Alangaden GJ; Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI, USA.

J Pharm Pract ; 36(3): 584-587, 2023 Jun.

Article en En | MEDLINE | ID: mdl-35090351

Asunto(s)

Clostridioides difficile; Infecciones por Clostridium; Humanos; Antibacterianos/uso terapéutico; Anticuerpos Neutralizantes/efectos adversos; Estudios Retrospectivos; Recurrencia; Infecciones por Clostridium/tratamiento farmacológico; Infecciones por Clostridium/prevención & control

Palabras clave

Clostridiodes difficile; bezlotoxumab; immunocompromised; infectious disease

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Clostridioides difficile / Infecciones por Clostridium Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Pharm Pract Asunto de la revista: FARMACIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google